Precipio Announces 2018 Year-End Corporate Update Call for Shareholders
April 15 2019 - 9:15AM
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO)
will be hosting its 2018 year-end corporate update call on
Monday, May 6 at 5:00 PM ET, following the expected filing on April
16 of its form 10-K and release of its financial results for
the fiscal year ending December 31, 2018.
Additionally, Nasdaq has scheduled Precipio’s compliance hearing
for May 2nd, 2019. The shareholder call will take place following
the company’s completion of the necessary actions intended to
regain compliance with its Nasdaq listing requirements relating to
the bid price of minimum $1.00. In addition to the financial review
of the year-end results, management will review the actions that
led to its share price exceeding the $1.00 threshold required to
regain compliance, and the company’s plans for continued share
price appreciation.
The conference call may be accessed by calling 866-524-3159
(international callers dial 1- 412-317-6759). All callers should
ask for the Precipio Inc. conference call. Participants may also
pre-register for the conference call at
http://dpregister.com/10130839 and will receive a
calendar invite and a direct dial-in number, bypassing the
operator.
Listeners interested in submitting questions in advance should
email their questions to investors@precipiodx.com and
management will do its best to address those questions during the
call.
A replay of the call will be available approximately 24 hours
after the call and may be accessed via the Investors page on
Precipio’s website, http://www.precipiodx.com/investors.html.
About Precipio
Precipio has built a platform designed to eradicate the problem
of misdiagnosis by harnessing the intellect, expertise and
technology developed within academic institutions and delivering
quality diagnostic information to physicians and their patients
worldwide. Through its collaborations with world-class academic
institutions specializing in cancer research, diagnostics and
treatment such as the Yale School of Medicine and Harvard’s
Dana-Farber Cancer Institute, Precipio offers a new standard of
diagnostic accuracy enabling the highest level of patient care. For
more information, please visit www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements,” within the meaning of federal
securities laws, including statements related to ICP technology,
including financial projections related thereto and potential
market opportunity, plans and prospects and other statements
containing the words “anticipate,” “intend,” “may,” “plan,”
“predict,” “will,” “would,” “could,” “should,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the known risks, uncertainties
and other factors described in the Company’s definitive proxy
statement filed on May 29, 2018, the Company’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2018 and on the
Annual Report on Form 10-K for the year ended December 31, 2017 as
well as the Company’s prior filings and from time to time in the
Company’s subsequent filings with the Securities and Exchange
Commission. Any change in such factors, risks and uncertainties may
cause the actual results, events and performance to differ
materially from those referred to in such statements. All
information in this press release is as of the date of the release
and the Company does not undertake any duty to update this
information, including any forward-looking statements, unless
required by law.
Inquiries:
investors@precipiodx.com
+1-203-787-7888
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Apr 2023 to Apr 2024